Kenneth A. Myszkowski
Net Worth

Last updated:

What is Kenneth A. Myszkowski net worth?

The estimated net worth of Mr. Kenneth A. Myszkowski is at least $42,228,801 as of 6 Mar 2024. He owns shares worth $7,935,886 as insider, has earned $23,938,415 from insider trading and has received compensation worth at least $10,354,500 in Arrowhead Pharmaceuticals, Inc..

What is the salary of Kenneth A. Myszkowski?

Mr. Kenneth A. Myszkowski salary is $690,300 per year as Chief Financial Officer in Arrowhead Pharmaceuticals, Inc..

How old is Kenneth A. Myszkowski?

Mr. Kenneth A. Myszkowski is 59 years old, born in 1966.

What stocks does Kenneth A. Myszkowski currently own?

As insider, Mr. Kenneth A. Myszkowski owns shares in one company:

Company Title Shares Price per share Total value
Arrowhead Pharmaceuticals, Inc. (ARWR) Chief Financial Officer 400,600 $19.81 $7,935,886

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR logo
ARWR
Arrowhead Pharmaceuticals, Inc.
$19.81

Kenneth A. Myszkowski insider trading

Arrowhead Pharmaceuticals, Inc.

Mr. Kenneth A. Myszkowski has made 34 insider trades between 2010-2024, according to the Form 4 filled with the SEC. Most recently he sold 40,000 units of ARWR stock worth $1,407,600 on 6 Mar 2024.

The largest trade he's ever made was exercising 81,875 units of ARWR stock on 17 Jan 2019. As of 6 Mar 2024 he still owns at least 400,600 units of ARWR stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 40,000 $35.19 $1,407,600
Sale
Common Stock 5,800 $34.97 $202,826
Sale
Common Stock 8,904 $35.65 $317,428
Sale
Common Stock 1,400 $34.04 $47,656
Sale
Common Stock 15,000 $36.2 $543,000
Sale
Common Stock 30,625 $40 $1,225,000
Sale
Common Stock 15,908 $60.5 $962,434
Sale
Common Stock 16,528 $62 $1,024,736
Sale
Common Stock 3,778 $63.17 $238,656
Sale
Common Stock 3,786 $63.95 $242,115
Sale
Common Stock 1,441 $81 $116,721
Sale
Common Stock 11,597 $81.02 $939,589
Sale
Common Stock 30,625 N/A N/A
Sale
Common Stock 30,625 $71.72 $2,196,333
Sale
Common Stock 43,505 $69.45 $3,021,422
Option
Stock Option (right to buy) 43,505 $14.54 $632,563
Sale
Common Stock 43,505 $69.45 $3,021,422
Option
Common Stock 43,505 $14.54 $632,563
Option
Common Stock 29,166 $6.15 $179,371
Sale
Common Stock 29,166 $6.15 $179,371
Option
Stock Option (right to buy) 29,166 $6.15 $179,371
Option
Stock Option (right to buy) 43,445 $8.71 $378,232
Option
Common Stock 43,445 $8.71 $378,232
Sale
Common Stock 40,313 $49.55 $1,997,429
Option
Stock Option (right to buy) 33,351 $5.19 $173,092
Option
Common Stock 33,351 $5.19 $173,092
Sale
Common Stock 20,000 $60.32 $1,206,340
Option
Stock Option (right to buy) 12,649 $5.19 $65,648
Option
Common Stock 12,649 $5.19 $65,648
Option
Stock Option (right to buy) 37,884 $7.75 $293,601
Sale
Common Stock 37,884 $40.89 $1,548,887
Option
Common Stock 37,884 $7.75 $293,601
Option
Common Stock 35,000 $4.9 $171,325
Option
Stock Option (right to buy) 35,000 $4.9 $171,325
Sale
Common Stock 27,071 $22 $595,562
Sale
Common Stock 8,000 $5.2 $41,600
Option
Stock Option (right to buy) 8,000 $5.2 $41,600
Option
Common Stock 8,000 $5.2 $41,600
Sale
Common Stock 81,875 $14.55 $1,191,281
Sale
Common Stock 8,333 $11.98 $99,829
Option
Common Stock 45,000 $11.82 $531,675
Option
Stock Option (right to buy) 45,000 $11.82 $531,675
Sale
Common Stock 45,000 $11.82 $531,675
Option
Common Stock 20,000 $2.01 $40,200
Option
Stock Option (right to buy) 20,000 $2.01 $40,200
Sale
Common Stock 20,000 $2.01 $40,200
Option
Stock Option (right to buy) 12,600 $11 $138,600
Option
Common Stock 12,600 $11 $138,600
Sale
Common Stock 12,600 $11 $138,600
Option
Stock Option (right to buy) 1,400 $2.01 $2,814
Sale
Common Stock 1,400 $2.01 $2,814
Option
Common Stock 1,400 $2.01 $2,814
Option
Common Stock 20,000 $2.01 $40,200
Sale
Common Stock 20,000 $2.01 $40,200
Option
Stock Option (right to buy) 20,000 $2.01 $40,200
Sale
Common Stock 6,900 $8 $55,200
Option
Stock Option (right to buy) 6,900 $8 $55,200
Option
Common Stock 6,900 $8 $55,200
Option
Common Stock 13,100 $2.01 $26,331
Sale
Common Stock 13,100 $2.01 $26,331
Option
Stock Option (right to buy) 13,100 $2.01 $26,331
Sale
Common Stock 23,347 $6.13 $143,117
Option
Common Stock 40,000 $6.1 $243,800
Option
Stock Option (right to buy) 40,000 $6.1 $243,800
Sale
Common Stock 40,000 $14.02 $560,880
Sale
Common Stock 16,000 $2.01 $32,160
Option
Common Stock 16,000 $2.01 $32,160
Option
Stock Option 16,000 $2.01 $32,160
Purchase
Common Stock 15,000 $0.89 $13,350

Arrowhead Pharmaceuticals key executives

Arrowhead Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: